Presenting the Best Evidence About a Controversial New Alzheimer ’s Drug: Q & A with Dr. Steven Woloshin

Steven Woloshin, MD, MS, a professor of medicine and community and family medicine, and co-director of the Master of Health Care Delivery Science program at The Dartmouth Institute for Health Policy and Clinical Practice, discusses the controversy surrounding the FDA’s approval of Aducanumab—a new drug to treat mild Alzheimer disease.

Source: News at Dartmouth Medical School - June 7, 2022 Category: Hospital Management Authors: Timothy Dean Tags: News Research Alzheimer’s Steven Woloshin Source Type: news